Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T14:57:13.252Z.
Calculation as of: 2026-10-06T14:57:13.252Z.
Quote observation: 2026-10-06T14:54:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cc1b6a3b00dabe5b261e15a58cf0fecaa0dcd4715ed4b38f5f86d2c12a5f1f47
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Cellyan Biotechnology Co., Ltd
Market Cap
$1.11M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.04M
EV/Sales Ratio
N/A
TTM Avg
26520.58x
3Y Avg
26520.58x
5Y Avg
26520.58x
Market Cap
$1.18M
EV/Sales Ratio
21.72x
TTM Avg
279.56x
3Y Avg
279.56x
5Y Avg
279.56x
Market Cap
$870069.00
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$865985.00
EV/Sales Ratio
N/A
TTM Avg
48327.79x
3Y Avg
43699.06x
5Y Avg
43699.06x
Market Cap
$835190.00
EV/Sales Ratio
N/A
TTM Avg
78.84x
3Y Avg
47.25x
5Y Avg
902.93x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellyan Biotechnology Co., Ltd (HKPD) | $1.11M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.04M | N/A | 26520.58x | 26520.58x | 26520.58x |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | 21.72x | 279.56x | 279.56x | 279.56x |
| IM Cannabis Corp. (IMCC)vs › | $1.19M | 0.33x | 0.51x | 0.45x | 1.23x |
| Bone Biologics Corporation (BBLG)vs › | $870069.00 | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.34M | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $865985.00 | N/A | 48327.79x | 43699.06x | 43699.06x |
| Decoy Therapeutics Inc. (DCOY)vs › | $835190.00 | N/A | 78.84x | 47.25x | 902.93x |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
